Qiu L, et al. - Researchers analyzed data from relevant studies identified from PubMed, EMBASE, Web of Science and the Cochrane Library to assess the prognostic and clinicopathological significance of programmed cell death receptor 1 ligand 1 (PD-L1) expressed in tumor cells of patients with diffuse large B-cell lymphoma (DLBCL). They assessed survival outcomes by using hazard ratio (HR) and 95% confidence interval (95% CI) and clinicopathological parameters by using the odds ratio (OR). According to the pooled data, poor overall survival, the non-germinal center B-cell-like subtype, high international prognostic index score (3–5), B symptoms, positive MUM1 expression, and negative BCL6 expression were reported in relation to tumor cell PD-L1 expression. in DLBCL patients, tumor cell PD-L1 expression could be a promising prognostic biomarker and was related to adverse clinicopathologic characteristics.